Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma

NCT00210366 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

OTHER

Sponsor class

Stopped due to slow accrual

Conditions

Lymphoma, B-Cell

Interventions

DRUG: Idarubicin

Sponsor

International Extranodal Lymphoma Study Group (IELSG)